Artivion, Inc.

Artivion, Inc.

AORTNYSE / NASDAQHealthcareSmall cap

$18.16-$0.37 (-2.0%)

Last close · Data as of Nov 20, 2026

Market cap
$1.0B
P/E
103.7x
EV / EBITDA
18.9x
Revenue
$441.3M
Net margin
2.2%
ROCE
6.2%

-58.8% over the last year

Artivion, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-21.4%
3M
-35.1%
6M
-19.9%
1Y
-58.8%
5Y
-4.2%

52-week range

Day change -$0.37 (-2.0%) from $19 to $18 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AORT, bought on each weekday since 2021.

News & filings

What Artivion filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe price is 34.7% below its 200-day average, and the 50-day average is below the 200-day.

Strengths (1)

  • Operating margin of 6.1% against a peer median of 2.0%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.

Read moreShow less

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Sector
Healthcare
Shares outstanding
47.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.0B
P/E
103.7x
P/B
2.3x
EV / EBITDA
18.9x
EV / Sales
2.7x
P/S
2.3x
52-week high
$47.18
52-week low
$18.16

Profitability

Operating margin
6.1%
Net margin
2.2%
EBITDA margin
14.5%
ROE
2.2%
ROCE
6.2%
ROA
1.1%
Asset turnover
0.50

Growth

Revenue
$441.3M
Revenue growth, 1Y
13.6%
Revenue CAGR, 3Y
12.0%
Net profit growth, 1Y
-173.1%
Free cash flow
$839.0k

Solvency

Current ratio
3.53
Debt / Equity
0.57
Debt / Assets
0.29
CFO / Net profit
4.09
Cash / Market cap
6.4%

Where the revenue went

Of every $100 of FY2025 revenue, $2 was left as net income.

Artivion, Inc. income statement flow, FY2025
Artivion, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$157.1M
RevenueGross profit$284.2M
Gross profitResearch and development$31.0M
Gross profitSelling, general and administrative$226.5M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$26.7M
Operating incomePretax income$14.8M
Operating incomeInterest and other expense$12.0M
Pretax incomeTax and other$5.0M
Pretax incomeNet income$9.8M

Revenue and net profit

Revenue grew 13.6% in FY2025; net profit is the dashed line.

Artivion, Inc. revenue and net profit by fiscal year
Artivion, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$313.8M-$19.2M
FY2023$354.0M-$30.7M
FY2024$388.5M-$13.4M
FY2025$441.3M$9.8M

Cash flows

FY2025: $39.9M from operations, $839.0k free after investment (dashed).

Artivion, Inc. operating and free cash flow by fiscal year
Artivion, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$5.2M-$15.9M
FY2023$18.8M$9.1M
FY2024$22.2M$11.0M
FY2025$39.9M$839.0k

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$441.3M+13.6%1Y
EBITDA
$63.8M+25.2%1Y
Net profit
$9.8M
Cash from operations
$39.9M+79.3%1Y
Free cash flow
$839.0k-92.4%1Y
Revenue CAGR, 3Y
12.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$441.3M$63.8M$9.8M$839.0k2.2%+13.6%-173.1%

Monthly returns

Month-by-month returns of AORT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$884.8M
Liabilities$436.6M
Equity$448.2M
Paid-in capital$516.6M
Retained earnings-$51.5M
Treasury stock$14.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AORT highlighted.

P/E against peers

AORT trades at 103.7x earnings against a peer median of -2.7x.

  1. Artivion, Inc. (this company)103.7x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Corvus Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Artivion, Inc.AORTthis company$1.0B103.7x2.3x2.2%18.9x
Collegium Pharmaceutical, Inc.COLL$1.1B16.9x3.5x20.8%4.1x
CONMED CorporationCNMD$1.1B22.5x1.0x4.6%10.5x
Azenta, Inc.AZTA$1.1B-18.9x0.6x-3.2%20.8x
The Pennant Group, Inc.PNTG$1.0B35.4x3.1x8.9%24.4x
QuidelOrtho CorporationQDEL$1.0B-0.9x0.5x-58.9%-7.7x
EyePoint, Inc.EYPT$1.0B-4.4x3.4x-75.8%-4.1x
Corvus Pharmaceuticals, Inc.CRVS$985.5M-64.5x16.1x-25.0%-22.9x
InnovAge Holding Corp.INNV$977.3M-32.2x4.2x-12.9%-102.4x
Peer median—-2.7x3.3x-8.1%-0.0x

Year-to-date ROI

AORT since 1 January, against earlier years.

Historical volatility

AORT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Artivion, Inc. operating margin by fiscal year
Artivion, Inc. operating margin by fiscal year
DateOperating margin
FY20222.0%
FY2023-2.4%
FY202410.0%
FY20256.1%
LineFY2025
Cost of revenueCost Of Revenue$157.1M
Gross profitGross Profit$284.2M
Operating expensesOperating Expense$257.5M
Research and developmentResearch And Development$31.0M
Selling, general and administrativeSelling General And Administration$226.5M
Total expensesTotal Expenses$414.6M
Pretax incomePretax Income$14.8M

Learn while you research

Academy chapters picked for Artivion, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 103.7, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →